Cost to Achieve an Undetectable Viral Load Using Recommended Antiretroviral Regimens

REFERENCES

• Bartlett JG. 1999 Medical Management of HIV Infection. Baltimore, MD: Johns Hopkins University; 1999.
   Google Scholar
• Bartlett JG. 2000–2001 Medical Management of HIV Infec-tion. Baltimore, MD: Johns Hopkins University; 2000.
   Google Scholar
• Bartlett JG. 2001–2002 Medical Management of HIV Infec-tion. Baltimore, MD: Johns Hopkins University; 2001.
   Google Scholar
• Bartlett JG. 2003 Medical Management of HIV Infection. Baltimore, MD: Johns Hopkins University; 2003.
   Google Scholar
• Fuhrmans V. Abbot lifts price of Norvir 400%. Wall Street Journal. December 19, 2003.
   Google Scholar
• Davis MD, Aldridge C. National ADAP Monitoring Project Annual Report, May 2004. Available at: http://www.atdn.orgadap/access//adap04.pdf.
   Google Scholar
• Kates J, Penner M, Crutsinger-Perry B, Leggoe AW, Singleton N. National ADAP Monitoring Project: Annual Report, Executive Summary, April 2005. Available at: http://www.kff.org/hivaids/upload/National-ADAP-Moni-toring-Project-Annual-Report-Executive-Summary-2005.pdf. Accessed September 5, 2005.
   Google Scholar
• Sendi PP, Bucher HC, Harr T, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients: Swiss HIV Cohort Study. AIDS. 1999;13: 1115–1122.
   PubMed Web of Science ®Google Scholar
• Cook J, Dasbach E, Coplan P, et al. Modeling the long-term outcomes and costs of HIV antiretroviral therapy us-ing HIV RNA levels: application to a clinical trial. AIDS Res Hum Retroviruses. 1999;15:499–508.
   PubMed Web of Science ®Google Scholar
• Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection: an economic perspective. Pharmacoeconomics. 1996;10:109–113.
   PubMed Web of Science ®Google Scholar
• Moore R. Cost effectiveness of combination HIV therapy: 3 years later. Pharmacoeconomics. 2000;17:325–330.
   PubMed Web of Science ®Google Scholar
• Keiser P, Kvanli MB, Turner D, et al. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administra-tion hospital. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:28–33.
   PubMedGoogle Scholar
• Ruane PJ, Ida J, Zakwski PC, Sokolov RJ, Uman SJ, Daly R. Impact of newer antiretroviral (ARV) therapies on inpa-tient and outpatient utilization of healthcare resources in patients with HIV. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22–26, 1997; Washington, DC. Abstract 466.
   Google Scholar
• Grimes R, Goodly J. Cost of achieving an undetectable viral load for various HAART regimens in adults using a protease inhibitor or efavirenz. In: Program and abstracts of the XIIIth International AIDS Conference; July 9–14, 2000; Durban South Africa. Abstract PeC5426.
   Google Scholar
• Panel on Clinical Practices for Treatment of HIV Infection, Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. April 7, 2005. Available at: http://aidsinfo.nih.gov/guidelines/adult/AA_040705.pdf. Ac-cessed September 5, 2005.
   Google Scholar
• Schrey G. The HIV Trial Guide: A Guide to Major Studies, Trials and Acronyms of HIV Antiretroviral Therapy 1985-2004. 3rd ed. The Netherlands: Van Zuiden Communica-tions BV; 2004.
   Google Scholar
• 2005 Red Book: Pharmacy's Fundamental ReferenceTM. Montvale, NJ: Thomson; 2005.
   Google Scholar
• Gallant J, Seekins D, Hicks C, et al. A phase II, double blind placebo controlled dose ranging study to assess the antiretroviral activity and safety of Efavirenz in combination with open label AZT/3TC at 48 weeks.AIDS. 1998;12\(suppl 4):S35.
   Google Scholar
• Stein A, Luskin-Hawk R, Pegram S, et al. Efficacy of Efavirenz (EFV) in combination with Stavudine (d4T) and Didanosine (ddl) in antiretroviral therapy-naive HIV-in-fected patients (Study 044). In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999; San Francisco. Abstract 1982.
   Google Scholar
• Molina JM, Perusat S, Ferchal F, et al. Once-daily combi-nation therapy with emtricitabine, didanosine and efavirenz in treatment-naive HIV-infected adults: 64-week follow-up of the ANRS 091 trial. In: Program and abstracts of the Eighth Conference on Retroviruses and Opportunistic In-fections; February 2–4, 2001; Chicago, IL. Abstract 321
   Google Scholar
• Landman R, Schiemann R, Thiam S, et al. Once-a-day highly active antiretroviral therapy in treatment naive HIV-1 infected adults in Senegal. AIDS. 2003;17:1017–1022.
   PubMed Web of Science ®Google Scholar
• Cohen C, Elion R, Green S, et al. Sustiva (Efavirenz) is highly effective and well tolerated in combination with the nucleosides Stavudine [Zerit] and lamivudine [Epivir] (Study DMP 266 043). In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Che-motherapy; September 17–20, 2000; Toronto, Canada. Abstract 538.
   Google Scholar
• Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the treatment of HIV-1 infection in adults (48 weeks). Study 006 Team. N Engl J Med. 1999;341:1865–1873.
   PubMed Web of Science ®Google Scholar
• Friedl AC, Lederberger B, Flepp M, et al. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. AIDS. 200115: 1793–1800.
   Google Scholar
• Squires KE, Thiry A, Giordano M, et al. Atazanavir QD and Efavirenz QD with fixed dose AZT/3TC: comparison of antiviral efficacy and safety through week 48. In: Program and abstracts of the 42nd ICAAC; 2002; San Diego, CA. Abstract 1076.
   Google Scholar
• Lucas GM, Gebo KA, Chaisson RE, et al. Comparison of initial combination antiretroviral therapy with a single pro-tease inhibitor, Ritonavir and Saquinavir, or Efavirenz. AIDS. 2001;15:1679–1686.
   PubMed Web of Science ®Google Scholar
• Haas D, Seekins R, Cooper R, et al. A phase II, double-blind, placebo-controlled, dose-ranging study to assess the antiretroviral activity and safety of Efavirenz (EFV, Sustiva, DMP 266) in combination with open-label Zidovudine (ZDV) with Lamivudine (3TC) at 36 weeks [DMP 266-005]. In: Program and abstracts of the 12th World AIDS Conference; 1998; Geneva. Abstract 22334.
   Google Scholar
• Matthews GV, Mandalia S, Nelson M, Bower M, Gizzard BG.. Does the choice between NNRTI or PI based initial HAART predict virological suppression at 24 weeks in a clinical setting? Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, Abstract P60. AIDS. 2000;14\(suppl 4):533.
   Google Scholar
• Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naIve patients: a randomized trial. JAMA. 2004;292(2):180–189.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Migliorino M, Maserati R. Once-a-day treat-ment for HIV infection: final 48-week results. In: Program and abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections; February 2–4, 2001; Chicago, IL. Abstract 320.
   Google Scholar
• Domula MR, Wasmuth JC, Jütte A. A Comparison of AZT/ 3TC vs. 3TC/d4T and ddl/d4T in combination with efavirenz as first line therapy: efficacy and safety results after 48 weeks. In: Program and abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections; February 24–28, 2002; Seattle, WA. Abstract 408 W.
   Google Scholar
• Nunez M, Soriano V, Martin-Carbonero L, Barrios A, et al. SENC (Spanish Efavirenz vs. Nevirapine Comparison) trial: a randomized, controlled, open-label study in HIV-infected naive individuals. HIV Clin Trials. 20023(3):186–194.
   Google Scholar
• Luskin-Hawk R, Cohen C, Lang J, et al. Efavirenz is well tolerated and highly efficacious in combination with the nucleosides Stavudine + Didanosine or Lamivudine. From: Abstract and poster presentation 349 at the 37th Annual Meeting of the Infectious Diseases Society of America (IDSA); November 18–21, 1999; Philadelphia, Pennsylvania.
   Google Scholar
• Arribas JR, Pulido F, Miro JM, et al. High effectiveness of Efavirenz-based HAART in HIV-1 infected patients with less than 100 CD4 cells/pL and opportunistic diseases. In: Pro-gram and abstracts of the XIV International AIDS Confer-ence; 2002; Barcelona. Abstract B4444.
   Google Scholar
• Montaner JG, Saag M, Bari!sky C, Siemon-Hryczyk P. FO-CUS study: saquinavir QD regimen versus efavirenz QD regimen 24-week analysis in HIV infected patients. In: Pro-gram and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2001; Chicago, IL. Abstract 670, p. 324.
   Google Scholar
• Van Leth F, Hassink E, Phanuphak P, et al. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either Nevirapine alone, Efavirenz alone or both drugs combined, together with Stavudine and Lamivudine. In: Program and abstracts of the 10th Conference on Retroviruses and Op-portunistic Infections; February 10–14, 2003; Boston. Ab-stract 176.
   Google Scholar
• DeJesus E, McCarty D, Farthing CF, et al. Once-daily ver-sus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis. 2004 ; 39 (3): 411–418 .
   PubMed Web of Science ®Google Scholar
• van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in H1V-1-infected patients. AIDS. 2003;17(7):987–999.
   PubMed Web of Science ®Google Scholar
• Floridia M, Bucciardini R, Ricciardulli D, et al. A random-ized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. J Acquir Immune Defic Syndr Human Retrovirol. 1999;20:11–19.
   PubMedGoogle Scholar
• Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients. JAMA. 1998;279:930–937.
   PubMed Web of Science ®Google Scholar
• French M, Amin J, Roth N, et al. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously un-treated H1V-1 infection. HIV Clin Trials. 20023(3):177–185.
   Google Scholar
• Viramune® The Treatment of Choice. Available at: www.hivandhepatitis.com/hiv_and_aids/viramune_1.html.
   Google Scholar
• Sanne I, Pilireo P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (A1424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. JA/DS. 2003;32(1):18–29.
   Google Scholar
• REYATAZ, product labeling, Bristol-Myers Squibb, July 2004.
   Google Scholar
• Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, random-ized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17: 2603–2614.
   PubMed Web of Science ®Google Scholar
• Murphy R, Pokrovsky V, Rozenbaum W, et al. Long term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir: 108 week results of BMS008/044. In: Program and abstracts of the 10th CR01; 2003; Boston. Abstract 555.
   Google Scholar
• Rodreguez-French A, Boghossain J, Gray GE, et al. The NEAT study: a 48-week-open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve H1V-1-infected patients. JA/DS. 2004;35(1):22–32.
   Google Scholar
• Gathe JC Jr., Lye P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ ritonavir versus twice-daily nelfinavir in naïve HIV-1-in-fected patients. AIDS. 2004;18(11):1529–1537.
   PubMed Web of Science ®Google Scholar
• Saag MS, Tebas P, Sension M, et al. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS. 2001;15(15):1971–1978.
   Web of Science ®Google Scholar
• Gartland M. AVANT! 3: a randomized, double-blinded trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in H1V-1-infected antiretroviral-naive patients. Antiviral Ther. 2001;6:127–134.
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Ferrer E, Consiglio E, et al. Final 12 month results from the COMBINE study: a randomized open, multicenter trial comparing Combivir plus nelfinavir or nevirapine in naive patients. In: Program and abstracts of the First International AIDS Society Conference on HIV Pathogenesis and Treatment; 2001; Buenos Aires. Ab-stract 7.
   Google Scholar
• Gathe J, Badaro R, Grimwood A, et al. Comparison of a triple combination regimen containing an enteric-coated formulation of didanosine administered once daily versus a regimen of combivir plus nelfinavir. In: Program and ab-stracts of the Eighth Conference on Retroviruses and Op-portunistic Infections; February 4–8, 2001; Chicago, IL. Abstract 319.
   Google Scholar
• King M, Bernstein E, Kempf D, et al. Comparison of time to achieve HIV RNA less than 400 copies/mL and less than 50 copies/mL in a phase III, blinded randomized clinical trial of Kaletra vs. nelfinavir in ARV-naive patients. In: Program and abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections; 2001; Chicago, IL. Abstract 329.
   Google Scholar
• Walmsley S, Badley A, Beall G, et al. Superior efficacy of ABT-378/r vs. nelfinavir (NFV) in antiretroviral (ARV)-naive subjects: results of a phase III blinded randomized clinical trial. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto, Ontario, Canada. Abstract 693.
   Google Scholar
• Peterson A, Antunes F, Arasteh K, et al. A comparison of long-term antiviral efficacy of BID and TID dosing of viracept in combination with stavudine and lamivudine. In: Program and abstracts of the Seventh ECCAT; 1999; Lisbon, Portugal. Abstract 250.
   Google Scholar
• VIRACEPT product labeling, Agouron Pharmaceuticals, Inc., April 2004.
   Google Scholar
• VIDEX product labeling, Bristol-Myers Squibb Company, January 2004.
   Google Scholar
• Fisch! M, Young B, Watkins B, et al. Direct study: a multicenter, open-label, 24-week pilot study with a 24-week extension to evaluate the safety, tolerability and effi-cacy of indinavir-ritonavir 800/100 bid in combination with d4T plus 3TC in HIV-infected individuals. In: Program and abstracts of the 41st Interscience Conference on Antimi-crobial Agents and Chemotherapy; 2001; Chicago, IL. Ab-stract 1–1923.
   Google Scholar
• Castagna A, Dragsted UB, Chave J-P, et al. The interim analysis of a phase IV randomized, open-label, multicenter trial to evaluate safety and efficacy of indinavir/ritonavir (800/100 mg bid) versus saquinavir/ritonavir (1,000/100 mg bid) in adult HIV-1 infection: MaxCmin1 Trial. In: Program and abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle, WA. Ab-stract 450–W.
   Google Scholar
• Voigt E, Wickesberg A, Wasmuth JC, et al. First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. HIV Med. 2002;3:277–282.
   PubMedGoogle Scholar
• Boyd M, Duncombel C, Ruxrungthram K, et al. Indinavir TID vs. indinavir/ritonavir BID in combination with AZT/3TC for HIV infection in nucleoside pretreated patients: HIV-NAT 005 76-week follow up. HIV-NAT 005. Presented at: 9th Conference on Retroviruses and Opportunistic Infec-tions; 2002; Seattle, WA. Abstract 422.
   Google Scholar
• Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001 ;15(1):1–9.
   PubMed Web of Science ®Google Scholar
• Landay A, Tokimoto D, King M, et al. Cytokine profiles of antiretroviral-naive HIV+ patients treated with lopinavir/ ritonavir (Kaletra)-based therapy for three years. In: Pro-gram and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 2003; Boston, MA. Abstract 578.
   Google Scholar
• Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-nafve HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265–267.
   PubMed Web of Science ®Google Scholar
• Gathe J, Podzamczer D, Johnson M, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral- naïve patients 48-week results. In: Program and abstracts of the 11th CR01; 2004; San Francisco, CA. Abstract 570.
   Google Scholar
• Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. New Engl J Med. 2002;346:2039–2046.
   PubMed Web of Science ®Google Scholar
• Grimes RM, Lal L, Lewis ST. Frequency of medical history items, drug interactions and lifestyle characteristics that may interfere with antiretroviral medications. HIV Clin Trial. 2002;3: 161–167.
   PubMedGoogle Scholar
• Ledergerber D, Egger M, Oprvil M, et al. Clinical progres-sion and virologic failure on highly active antiretroviral therapy in HIV-1 patients: a prospective study. Lancet. 1999;353:863–868.
   PubMed Web of Science ®Google Scholar
• Bini T, Testa L, Chiesa E, et al. Outcome of a second line protease inhibitor-containing regimens in patients failing or intolerant of a first highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;24:115–122.
   PubMed Web of Science ®Google Scholar